Ironwood Pharmaceuticals Inc (IRWD)

pos +0.00
Today's Range: 0.00 - 0.00 | IRWD Avg Daily Volume: 1,325,200
Last Update: 11/24/15 - 3:59 PM EST
Volume: 0
YTD Performance: -20.04%
Open: $0.00
Previous Close: $12.25
52 Week Range: $9.77 - $17.11
Oustanding Shares: 142,782,696
Market Cap: 1,561,942,769
6-Month Chart
TheStreet Ratings Grade for IRWD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.43 2.43 2.43 2.43
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -10.42
Price Earnings Comparisons:
IRWD Sector Avg. S&P 500
-10.42 0.00 32.53
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.17% -11.10% 12.59%
Revenue 234.10 0.16 0.05
Net Income 0.00 1.92 0.00
EPS 0.00 1.14 0.00
Earnings for IRWD:
Revenue 0.08B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $-0.17 $-0.13 $-0.99 $-0.32
Number of Analysts 7 2 5 7
High Estimate $-0.09 $-0.08 $-0.92 $-0.06
Low Estimate $-0.34 $-0.18 $-1.09 $-0.67
Prior Year $-0.27 $-0.24 $-1.33 $-0.99
Growth Rate (Year over Year) 37.04% 45.83% 25.56% 67.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Feb 06, 2015 | 7:43 AM EST
IRWD was upgraded form Sell to Hold, Cantor Fitzgerald said. Company lacks negative near-term catalysts. $13.50 price target. 
Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The
Nov 06, 2014 | 6:54 AM EST
IRWD was downgraded from Hold to Sell, Cantor Fitzgerald said. $10 price target. Valuation call, as the company will likely spend more ...
Jul 24, 2013 | 7:51 AM EDT
IRWD was upgraded to Hold, Cantor Fitzgerald said. $10 price target. Linzess can continue to grow and the company is keeping a tight li...
May 30, 2013 | 8:09 AM EDT
IRWD was upgraded from Underperform to Neutral, Wedbush said. $12 price target. Linzess prescriptions are growing.
The negative surprises indicate hidden weakness in a business, and the stocks are to be avoided.
Apr 24, 2013 | 8:17 AM EDT
Shares of IRWD were downgraded to Underperform  from Neutral, said Wedbush. Cash burn is occurring much faster than expected given...
Mar 15, 2013 | 8:18 AM EDT
IRWD was upgraded to Outperform, Credit Suisse said. $24 price target. Expect higher Linzess sales. 
Feb 13, 2013 | 8:38 AM EST
IRWD was upgraded to Neutral from Underperform, Wedbush said. $13 price target. LINZESS strong out of the gates. 
Jan 16, 2013 | 8:39 AM EST
IRWD was downgraded to Sell from Neutral, UBS said. $11.50 price target. Expectations too high. 

Columnist Conversations

Market holding up very well given news of downed Russian jet over Turkey today. However, it is still a very b...
Yesterday's Saudi announcement coupled with this morning's geopolitical tensions have combined to goose oil pr...
These refiners are stretching out here, the best turnover is in Valero, and we have seen some big option flow ...
Cracker Barrel is getting pounded today following this morning's earnings report. The stock is off over 7...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.